Colon-targeted celecoxib-loaded Eudragit ® S100-coated poly-ε-caprolactone microparticles: Preparation, characterization and in vivo evaluation in rats

Drug Delivery

Volumn 18, Issue 7, 2011, Pages 523-535

  Ghorab, Dalia M ^a   Amin, Maha Mohamed ^a   Khowessah, Omneya M ^a   Tadros, Mina Ibrahim ^a  

^a CAIRO UNIVERSITY   (Egypt)

Author keywords

factorial design; Inflammatory bowel disease; PH dependant coat; pharmacokinetics; time dependant coat

Indexed keywords

CELECOXIB; EUDRAGIT; NAPROXEN; POLYCAPROLACTONE;

ANIMAL EXPERIMENT; ANIMAL TISSUE; AREA UNDER THE CURVE; ARTICLE; COLON; CONTROLLED STUDY; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG COATING; DRUG HALF LIFE; DRUG RELEASE; DRUG SOLUBILITY; IN VIVO STUDY; MALE; MAXIMUM PLASMA CONCENTRATION; NONHUMAN; PARTICLE SIZE; PLASMA CONCENTRATION-TIME CURVE; PRIORITY JOURNAL; RAT; TIME TO MAXIMUM PLASMA CONCENTRATION;

ADMINISTRATION, ORAL; ANIMALS; BIOLOGICAL AVAILABILITY; COLON; CYCLOOXYGENASE 2 INHIBITORS; DELAYED-ACTION PREPARATIONS; DRUG CARRIERS; DRUG DELIVERY SYSTEMS; HYDROGEN-ION CONCENTRATION; MALE; MICROSPHERES; PARTICLE SIZE; POLYESTERS; POLYMETHACRYLIC ACIDS; PYRAZOLES; RATS; RATS, WISTAR; SULFONAMIDES; SURFACE-ACTIVE AGENTS; TIME FACTORS;

EID: 80052942407     PISSN: 10717544     EISSN: 15210464     Source Type: Journal    
DOI: 10.3109/10717544.2011.595841     Document Type: Article

References (37)

1. Abdallah M, Yuichi T, Hirofumi T. (2009). pH-Sensitive nanospheres for colon-specific drug delivery in experimentally induced colitis rat model. Eur J Pharm Biopharm, 72, 1-8.
2. Abdelbary GA, Tadros MI. (2008). Design and in vitro/in vivo evaluation of novel nicorandil extended release matrix tablets based on hydrophilic interpolymer complexes and a hydrophobic waxy polymer. Eur J Pharm Biopharm, 69, 1019-28.
3. Ali J, Tyagi P, Ahuja A, Baboota S, Hasan S. (2007). Development and evaluation of a gastroretentive drug delivery system for the lowabsorption-window drug celecoxib. PDA J Pharm Sci Technol, 61(2), 88-96. (Pubitemid 46651440)
4. Ardizzone S, Bianchi Porro G. (1998). A practical guide to the management of distal ulcerative colitis. Drugs, 55, 519-42. (Pubitemid 28162075)
5. Ashford M, Fell JT, Attwood D, Woodhead PJ. (1993). An in vitro investigation into the suitability of pH-dependent polymers for colonic targeting. Int J Pharm, 91, 241-45. (Pubitemid 23159828)
6. Barbato F, Rotonda MI, Maglio G, Palumo R, Quaglia F. (2001). Biodegradable microspheres of a novel segmented polyetherester-amides based on poly-ε-caprolactone for the delivery of bioactive compounds. Biomaterials, 22, 1371-78. (Pubitemid 32409959)
7. Campieri M, Ferguson A, Doe W, Persson T, Nilsson LG. (1997). Oral budesonide is as effective as oral prednisolone in active Crohns disease. The Global Budesonide Study Group. Gut, 41, 209-14. (Pubitemid 27395924)
8. Castellanos IJ, Carrasquillo KG, de Jesus Lopez J, Alvarez M, Griebenow K. (2001). Encapsulation of bovine serum albumin in poly(lactideco-glycolide) microspheres by the solid-in-oil-in-water technique. J Pharm Pharmacol, 53, 167-78. (Pubitemid 32156509)
9. Cheng SY, Yuen MC, Lam PL, Gambari R, Wong RS, Cheng GY, Lai PB, Tong SW, Chan KW, Lau FY, Kok SH, Lam KH, Chui CH. (2010). Synthesis, characterization and preliminary analysis of in vivo biological activity of chitosan/celecoxib microcapsules. Bioorg Med Chem Lett, 20(14), 4147-4151.
10. Chourasia MK, Jain SK. (2003). Pharmaceutical approaches to colon targeted drug delivery systems. J Pharm Sci, 6(1), 33-66. (Pubitemid 37207241)
11. de Heer P, Sandel MH, Guertens G, de Boeck G, Koudijs MM, Nagelkerke JF, Junggeburt JM, de Bruijn EA, van de Velde CJ, Kuppen PJ. (2008). Celecoxib inhibits growth of tumors in a syngeneic rat liver metastases model for colorectal cancer. Cancer Chemother Pharmacol, 62(5), 811-19.
12. Fu X, Ping Q, Gao Y. (2005). Effects of formulation factors on encapsulation efficiency and release behavior in vitro of huperzine A-PLGA microspheres. J Microencapsul, 22, 705-14. (Pubitemid 43158192)
13. Higuchi T. (1963). Mechanism of sustained action medication. J Pharm Sci, 52, 1145-49.
14. Homar M, Ubrich N, El Ghazouani F, Kristl J, Kerc J, Maincent P. (2007). Influence of polymers on the bioavailability of microencapsulated celecoxib. J Microencapsul, 24(7), 621-633. (Pubitemid 47343457)
15. Hu LD, Liu Y, Tang X, Zhang Q. (2006). Preparation and in vitro/in vivo evaluation of sustained-release metformin hydrochloride pellets. Eur J Pharm Biopharm, 64, 185-92. (Pubitemid 44291990)
16. Imaly JA, Linn S. (1988). DNA damage and oxygen radical toxicity. Science, 240, 1302-9.
17. Kondo H, Sharma RK, Mishra AK, Chuttani K, Murthy RR. (2005). Albumin microspheres as carriers for the antiarthritic drug celecoxib. AAPS PharmSciTech, 6 (1), E65-73. (Pubitemid 41630999)
18. Kondo N, Iwao T, Hirai K, Fukuda M, Yamanouchi K, Yokoyama K, Miyaji M, Ishihara Y, Kon K, Ogawa Y, Mayumi T. (1994). Improved oral absorption of enteric coprecipitates of a poorly soluble drug. J Pharm Sci, 4(83), 566-70. (Pubitemid 24222385)
19. Korsmeyer RW, Peppas NA. (1981). Effect of the morphology of hydrophilic polymeric matrices on the diffusion and release of water soluble drugs. J Membr Sci, (9), 211-27. (Pubitemid 12253072)
20. Krishnamachari Y, Madan P, Lin S. (2007). Development of pH-and time dependent oral microparticles to optimize budesonide delivery to ileum and colon. Int J Pharm, 348, 238-47. (Pubitemid 46777247)
21. Lamprecht A, Schafer U, Lehr CM. (2001). Size-dependent bioadhesion of micro-and nanoparticulate carriers to the inflamed colonic mucosa. Pharm Res, 18, 788-93. (Pubitemid 32783514)
22. Mahadevan U, Loftus EV Jr, Tremaine WJ, Sandborn WJ. (2002). Safety of selective cyclooxygenase-2 inhibitors in inflammatory bowel disease. Am J Gastroenterol, 97(4), 910-14. (Pubitemid 34408247)
23. Meissner Y, Pellequer Y, Lamprecht A. (2006). Nanoparticles in inflammatory bowel disease: particle targeting versus pH-sensitive delivery. Int J Pharm, 316, 138-43. (Pubitemid 43765696)
24. Nakase H, Okazaki K, Tabata Y, Uose S, Ohana M, Uchida K, Matsushima Y, Kawanami C, Oshima C, Ikada Y, Chiba T. (2000). Development of an oral drug delivery system targeting immune-regulating cells in experimental inflammatory bowel disease: a new therapeutic strategy. J Pharmacol Exp Ther, 292, 15-21. (Pubitemid 30026351)
25. Niederberger E, Tegeder I, Vetter G, Schmidtko A, Schmidt H, Euchenhofer C, Brätigam L, Gröch S, Geisslinger G. (2001). Celecoxib loses its anti-inflammatory efficacy at high doses through activation of NF-κB. The FASEB J, 15, 1622-24.
26. Paulson SK, Vaughn MB, Jessen SM, Lawal Y, Gresk CJ, Yan B, Maziasz TJ, Cook CS, Karim A. (2001). Pharmacokinetics of celecoxib after oral administration in dogs and humans: effect of food and site of absorption. J Pharmacol Exp Ther, 297 (2), 638-645. (Pubitemid 32377995)
27. Passerini N, Perissutti B, Albertini B, Voinovich D, Moneghini M, Rodriguez L. (2003). Controlled release of verapamil hydrochloride from waxy microparticles prepared by spray congealing. J Control Release, 88(2), 263-275. (Pubitemid 36287343)
28. Raffin RP, ColoméLM, Guterres SS, Pohlmann AR. (2007). Enteric Controlled-Release Pantoprazole-Loaded Microparticles Prepared by Using Eudragit S100 and Poly(ε-caprolactone) Blend. Pharm Dev Technology, 12(5), 463-71. (Pubitemid 350034880)
29. Rodriguez M, Vila-Jato JL, Torres D. (1998). Design of new multiparticulate system for potential site specific and controlled drug delivery to the colonic region. J Control Rel, 55, 67-77. (Pubitemid 28477565)
30. Simmonds NJ, Rampton DS. (1994). Inflammatory bowel disease: a radical view. Gut, 34, 861-5.
31. Sinha VR, Bhinge JR, Kumria R, Kumar M. (2006). Development of pulsatile systems for targeted drug delivery of celecoxib for prophylaxis of colorectal cancer. Drug Deliv, 13(3), 221-5.
32. Sinha VR, Bansal K, Kaushik R, Kumria R, Trehan A. (2004). Poly-ε-caprolactone microspheres and nanospheres: an overview. Int J Pharm, 278, 1-23.
33. Tan A, Simovic S, Davey AK, Rades T, Prestidge CA. (2009). Silicalipid hybrid (SLH) microcapsules: A novel oral delivery system for poorly soluble drugs. J Control Rel, 134, 62-70.
34. Thakkar H, Sharma RK, Mishra AK, Chuttani K, Murthy RR. (2005). Albumin microspheres as carriers for the antiarthritic drug celecoxib. AAPS PharmSciTech, 20;6(1), E65-73. (Pubitemid 41630999)
35. Thakkar H, Sharma RK, Mishra AK, Chuttani K, Murthy RS. (2004). Celecoxib incorporated chitosan microspheres: in vitro and in vivo evaluation. J Drug Target, 12(9-10), 549-557. (Pubitemid 40100702)
36. Yehia SA, Elshafeey AH, Sayed I, Shehata AH. (2009). Optimization of budesonide compression-coated tablets for colonic delivery. AAPS PharmSciTech, 10(1), 147-57.
37. Zvonar A, Kristl J, Kerc J, Grabnar PA.(2009). High celecoxibloaded nanoparticles prepared by a vibrating nozzle device. J Microencapsul, 26(8), 748-759.